Weight loss injections may ease PMOS symptoms and improve metabolic health, but experts warn they cannot cure underlying hormonal imbalances.
Sun Pharma gains CDSCO approval for oral semaglutide tablets, marking its entry into India’s competitive oral GLP-1 market.
Sun Pharma’s Q2 profit falls as acquisition costs rise, despite revenue growth and stronger operating performance across key business segments.
India's healthcare industry faces three defining shifts as drug pricing, weight-loss innovation, and pharmaceutical R&D reshape patient access and competition.
Omron's Chennai factory puts medical device localization in focus as India seeks domestic production, component sourcing and a larger role in global healthcare supply chains.
Patient accommodation infrastructure is gaining attention as AIIMS Delhi prepares to use BEL's new 897-seat facility to improve support for patients and attendants.
The US FDA clears Sun Pharma’s Ilumya for adults with active psoriatic arthritis, expanding the drug beyond its original 2018 approval for moderate-to-severe plaque psoriasis.
India’s pharma export numbers for the first half of FY27 reach USD 16.14 billion, a 4.9% rise from USD 15.38 billion a year earlier
Autoimmune drug discovery is gaining attention as ICMR backs a four-year Indian study exploring genetic links and shared treatment targets across affected families nationally.
World markets drive Strides Pharma’s 17% rise this quarter as the company’s non-US markets generate more revenue than its traditional American business for the first time.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
